hackint0sh/New-Dataset huggingface dataset:
Participants will complete a 7 week psychologist guided parenting intervention. Researchers will compare waitlist groups to see if there are differences in psychological flexibility, child behaviour, parent-child relationships, parental well-being or parental self-efficacy. conditions: Psychological Flexibility conditions: Child Behavior conditions: Relationship, Parent Child conditions: Well-Being, Psychological conditions: Self-efficacy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: This quantitative study will be a two arm randomised control trial with an intervention group and waitlist group. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: ACT Now GAIN Later name: Control Group measure: Parental Psychological Flexibility measure: Child Behaviour measure: Parent-Child Relationships measure: Parental Well-Being measure: Parental Self-Efficacy measure: Parental Self-Efficacy sex: ALL minimumAge: 3 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06339320 id: PRO00037835 briefTitle: Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity overallStatus: RECRUITING date: 2024-02-28 date: 2033-10 date: 2033-10 date: 2024-04-01 date: 2024-04-01 name: The Methodist Hospital Research Institute class: OTHER briefSummary: The purpose of this study is to evaluate endoscopic sleeve gastroplasty (ESG) for the treatment of obesity. The ESG procedure is an U.S. Food and Drug Administration (FDA) approved procedure for the treatment of obesity - patients with a body mass index (BMI) 30-50 kg/m2. This procedure is FDA approved; however, Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-Accredited centers (such as Houston Methodist Hospital) must receive approval from an Institutional Review Board (IRB) in order to perform primary procedures, such as ESG, that are not endorsed by the American Society for Metabolic and Bariatric Surgery (ASMBS). conditions: Endoscopic Sleeve Gastroplasty conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Retrospective Registry Study primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: Endoscopic Sleeve Gastroplasty (ESG) name: Apollo OverStitch endoscopic suturing device measure: Number of participants with technically successful completion of the ESG procedure measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 measure: Change in body mass index (BMI) measured by kg/m2 measure: Change in hemoglobin A1C (%) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Houston Methodist Hospital status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Thomas R McCarty, MD, MPH role: CONTACT phone: 713-363-7436 email: tommccarty3@houstonmethodist.org lat: 29.76328 lon: -95.36327 facility: Houston Methodist Hospital - Sugarland status: RECRUITING city: Sugar Land state: Texas zip: 77479 country: United States name: Thomas R McCarty, MD, MPH role: CONTACT phone: 713-363-7436 email: tommccarty3@houstonmethodist.org lat: 29.61968 lon: -95.63495 hasResults: False
nctId: NCT06339307 id: DJY004 briefTitle: A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients overallStatus: RECRUITING date: 2024-02-15 date: 2024-06-30 date: 2024-12-31 date: 2024-04-01 date: 2024-04-01 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability. conditions: Predictive Cancer Model conditions: Gastric Cancer conditions: Lymph Node Metastasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: lymph node metastasis sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital of Tianjin Medical University status: RECRUITING city: Tianjin state: Tianjin country: China name: Jingyu Deng, M.D. role: CONTACT phone: +86-22-23340123 email: dengery@126.com lat: 39.14222 lon: 117.17667 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-07-01 uploadDate: 2024-03-17T10:10 filename: Prot_000.pdf size: 131262 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2023-07-01 uploadDate: 2024-03-17T10:11 filename: SAP_001.pdf size: 158196 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-07-01 uploadDate: 2024-03-17T10:11 filename: ICF_002.pdf size: 151390 hasResults: False
nctId: NCT06339294 id: ZShabbir briefTitle: Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment overallStatus: COMPLETED date: 2023-06-16 date: 2023-12-15 date: 2023-12-31 date: 2024-04-01 date: 2024-04-01 name: Rawalpindi Medical College class: OTHER briefSummary: Background and Objectives To compare the efficacy of gel foam-soaked pyodine with a single topical application of clotrimazole ointment.
Subjects and Methods This randomized controlled trial will include 90 patients presenting to ENT OPD with complaints of earache, watery ear discharge, pruritis, and ear blockage and will be clinically diagnosed as a case of otomycosis on otoscopy. The external auditory canal of the patient will be cleared of fungal debris via suction before treatment In Group A ear canal will be filled with 1% clotrimazole ointment by using an IV catheter and syringe and in Group B pyodine-soaked gel foam will be placed in the external auditory canal. The patients will be followed up on post-treatment days 7 and 14. conditions: Otomycosis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 90 type: ACTUAL name: Clotrimazole Cream name: Povidone-Iodine measure: Treatment Response Based on Otoscopy measure: Condition of External Auditory Canal sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Benazir Bhutto Hospital city: Rawalpindi state: Punjab/46000 zip: 46000 country: Pakistan lat: 33.6007 lon: 73.0679 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-05-16 uploadDate: 2024-03-24T05:10 filename: Prot_SAP_000.pdf size: 557916 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-06-16 uploadDate: 2024-03-24T05:13 filename: ICF_001.pdf size: 1206939 hasResults: False
nctId: NCT06339281 id: 2023YJZ87 briefTitle: A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-06 date: 2026-12 date: 2024-04-01 date: 2024-04-19 name: Li Huiping class: OTHER briefSummary: Previous studies have found good efficacy of (investigator's choice of chemotherapy, or endocrine drug) in combination with apatinib mesylate in the treatment of her-2 negative, chest wall metastatic advanced breast cancer, and the present study proposes to further explore the efficacy of apatinib mesylate in her-2 negative, HR-positive advanced breast cancer. conditions: Advanced Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 68 type: ESTIMATED name: apatinib mesylate+Capecitabine Tablets name: apatinib mesylate+Fulvestrant injection measure: Progression-free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339268 id: MMABelgrade briefTitle: Cognitive and Physical Optimization in Prevention of Postoperative Cognitive Deficit in Elderly With Lung Resection acronym: COGNITION overallStatus: RECRUITING date: 2023-11-01 date: 2025-11-01 date: 2026-03-01 date: 2024-04-01 date: 2024-04-01 name: Military Medical Academy, Belgrade, Serbia class: OTHER briefSummary: Postoperative cognitive deficit and its connection with surgery and general anesthesia were first mentioned in the literature in 1955 by Bradford. Cognitive disorders in the postoperative period are postoperative delirium (POD) and postoperative cognitive dysfunction (POCD). POD is an acute dysfunction in cognition, which did not exist preoperatively. Attention deficit disorder is the main symptom of POD and refers to the inability to direct, focus, maintain, or shift attention. Memory impairment, disorientation, or perceptual disturbances may also be present. Cognitive capacity changes in POD patients develop and fluctuate in the first few days after surgery. Unlike POD, there is no formal definition for POCD. Based on data from the existing literature, it is defined as newly diagnosed cognitive deterioration that occurs after surgery. The diagnosis of POCD should be based on pre- and postoperative screening with appropriate psychometric tests. Risk factors for the development of POCD include those related to the surgical procedure, anesthesia, or the patient himself. Compared to less invasive and shorter operations, there is a higher risk of developing POCD after major, invasive, and long-term operations. Additional risk factors are intraoperative (intraoperative bleeding, perioperative transfusion treatment, hypotension) and postoperative complications (respiratory insufficiency, pneumonia, atelectasis, bronchospasm, bronchopleural fistula, and pulmonary edema). Presurgical optimization (Prehabilitation) is a widespread concept that aims to improve the general condition of the patient or optimize comorbidities before major surgery. Prehabilitation is primarily focused on improving physical ability and nutritional status, but it is developing in the direction of a multimodal approach that includes measures to reduce stress and anxiety. Psychological factors are increasingly recognized as an essential element of prehabilitation and are often added to prehabilitation programs.
2. The second group (control) where patients receive standard treatment. primaryPurpose: PREVENTION masking: NONE count: 120 type: ESTIMATED name: Cognitive training, CogniFit App measure: Postoperative cognitive dysfunction measure: Perioperative depression and anxiety measure: Postoperative delirium measure: Functional status and postoperative recovery measure: Functional status and postoperative recovery measure: Postoperative recovery measure: Functional status and postoperative recovery measure: Overall outcome: Complication rate measure: Overall outcome: Morbidity measure: Overall outcome: Mortality sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Military Medical Academy status: RECRUITING city: Belgrade zip: 11000 country: Serbia name: Vojislava Neskovic, PhD role: CONTACT phone: +381 64 1775 320 email: vojkan43@gmail.com name: Marija Markovic, MD role: CONTACT phone: +381 62 666653 email: markovicmarija@hotmail.com lat: 44.80401 lon: 20.46513 hasResults: False
nctId: NCT06339255 id: INT 180/19 briefTitle: Italian Observational Study on CAR-T Therapy for Lymphoma acronym: CART-SIE overallStatus: RECRUITING date: 2019-10-30 date: 2028-12-31 date: 2029-12-31 date: 2024-04-01 date: 2024-04-01 name: Paolo Corradini class: OTHER name: Annalisa Chiappella name: Cristiana Carniti name: Anna Dodero briefSummary: The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting.
Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity. conditions: Diffuse Low Grade B-Cell Lymphoma conditions: Primary Mediastinal Large B-cell Lymphoma (PMBCL) conditions: Mantle Cell Lymphoma conditions: Follicular Lymphoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 5300 type: ESTIMATED measure: Feasibility of the CAR-T cells treatment in lymphomas in the italian real life practice measure: Efficacy of the CAR-T cells treatment in lymphomas in the italian real life practice measure: Evaluation of Outcome: Overall Response rate (ORR), according to Lugano criteria. measure: Evaluation of Outcome: Overall survival (OS), according to Lugano criteria. measure: Evaluation of Outcome: Progression free survival (PFS) measure: Evaluation of Outcome: duration of response (DoR) measure: Evaluation of Outcome: Overall Response rate (ORR) measure: Evaluation of Outcome: Overall survival (OS) measure: Evaluation of Outcome: non-relapse mortality (NRM) measure: Evaluation of safety (CRS, neurotoxicity, infections, cytopenias, B cell aplasia, second malignancies) with particular attention to the safety in the new indications measure: Evaluation of bridging therapy: safety measure: Evaluation of bridging therapy: efficay measure: Evaluation of salvage therapy after CAR-T failure measure: Evaluation of salvage therapy after CAR-T failure measure: Comparison of the different CAR T-cell products (time from patient screening to infusion, disease response and safety) measure: Comparison of the different histotypes (PMBCL, DLBCL, MCL FL) according to CAR-T cell products measure: Characterization of biomarkers of early response (circulating tumor cell free DNA versus PET and CT scans) measure: Characterization of toxicity biomarkers measure: Analysis of the immune reconstitution measure: Analysis of the CAR-T expression measure: Influence of PET quantitative parameters: tMTV changes between baseline and +30 and +90 after CAR T-cell infusion (ΔSUV max) related to outcome measure: Influence of PET quantitative parameters: Distance max measure: Influence of PET quantitative parameters: Distance max bulky sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Istituto Nazionale Tumori status: RECRUITING city: Milan zip: 20133 country: Italy name: Paolo Corradini, Professor role: CONTACT phone: +39 02 2390 2950 email: paolo.corradini@istitutotumori.mi.it name: Anisa Bermema, PhD role: CONTACT phone: +39 02 2390 3145 email: anisa.bermema@istitutotumori.mi.it name: Annalisa Chiappella, MD role: SUB_INVESTIGATOR name: Anna Dodero, MD role: SUB_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06339242 id: 2024-01-NSCLC briefTitle: A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis overallStatus: RECRUITING date: 2024-01-01 date: 2025-07-01 date: 2026-01-31 date: 2024-04-01 date: 2024-04-01 name: Jiangsu Province Nanjing Brain Hospital class: OTHER briefSummary: Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The Furmonertinib prototype persists longer in brain tissue, and its metabolites can also penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly control the progression of intracranial lesions. The aim of this study is to evaluate the LM progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation EGFR-TKIs resistance. conditions: NSCLC studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Furmonertinib measure: LM-PFS（progression-free survival） measure: LM-ORR（Objective response rate） measure: LM-OS measure: Incidence of Treatment-Emergent Adverse Events measure: PFS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing Brain Hospital status: RECRUITING city: Nanjing state: Jiangsu zip: 210029 country: China name: fang S Cun role: CONTACT phone: 83728558 phoneExt: 025 email: fang1984@aliyun.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06339229 id: FSYYY-2024-12 briefTitle: Postoperative New-onset Proteinuria and Adverse Outcomes. overallStatus: COMPLETED date: 2000-01-01 date: 2022-12-31 date: 2023-11-01 date: 2024-04-01 date: 2024-04-01 name: Yaozhong Kong class: OTHER briefSummary: We aimed to assess the association between postoperative new-onset proteinuria, all-cause mortality, and decline in kidney function in Chinese people who underwent surgery. The exposure variable was the dipstick proteinuria values from the initial postoperative urinalysis within 30 days after surgery, categorized as negative, trace, 1+, and ≥2+. The primary outcome was 30-day mortality. The secondary outcomes included 1-year mortality and composite kidney outcome assessed using the postoperative estimated glomerular filtration rate. conditions: Surgery conditions: Proteinuria conditions: Mortality studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 2983899 type: ACTUAL name: proteinuria measure: mortality sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339216 id: OBU-BJ-GC-II-011 briefTitle: A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-12-30 date: 2026-11-30 date: 2024-04-01 date: 2024-04-01 name: Chinese PLA General Hospital class: OTHER briefSummary: Phase II Clinical Study of Adebrelimab Combined with Apatinib and Paclitaxel for Injection(Albumin Bound) as Second-line Therapy in Patients with Advanced Gastric Cancer Previously Treated with Immunotherapy conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound) measure: ORR measure: PFS measure: DCR measure: OS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06339203 id: 5240002 briefTitle: Intraoperative Wound Irrigation in Cesarean Section overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2025-12 date: 2024-04-01 date: 2024-04-01 name: Loma Linda University class: OTHER name: Irrimax Corporation briefSummary: This investigator-initiated, open-label, randomized controlled trial will explore the effects of two treatment arms, comparing standard treatment with normal saline against Irrisept, a jet lavage solution containing a low concentration of Chlorhexidine Gluconate (CHG) at 0.05% in 99.95% sterile water for irrigation. The study aims to evaluate the impact on postoperative wound healing in patients who have undergone cesarean delivery. conditions: Cesarean Section Complications conditions: Cesarean Section; Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 400 type: ESTIMATED name: Irrisept name: Normal Saline measure: Composite wound evaluation after caesarean delivery sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Loma Linda University city: Loma Linda state: California zip: 92354 country: United States name: Nikia Gray Hutto, AS role: CONTACT phone: 909-558-4000 phoneExt: 44428 email: nhutto@llu.edu lat: 34.04835 lon: -117.26115 hasResults: False
nctId: NCT06339190 id: E21-006-72840 briefTitle: Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis acronym: NAVAIDD overallStatus: RECRUITING date: 2021-08-01 date: 2025-12 date: 2027-12 date: 2024-04-01 date: 2024-04-01 name: Monash University class: OTHER name: Eastern Health name: University of Melbourne name: Wake Forest University name: Deakin University name: The Florey Institute of Neuroscience and Mental Health name: Invitae Corporation name: Redenlab briefSummary: This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.
Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample. conditions: Neurodegenerative Diseases conditions: Dementia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Venepuncture measure: Nfl correlation with neurodegeneration measure: Change in speech processing measure: Change in language processing measure: Change in Direct Magnitude Estimation measure: Modified Rankin Scale measure: Montreal Cognitive Assessment score measure: Hospital Anxiety and Depression Scale score measure: Clinical Global Impression score measure: WHO Disability Assessment 12-item telephone interview score measure: WHO Disability Assessment 36-item self report score measure: DNA sample for testing known pathogenic dementia mutations sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Box Hill Hospital status: RECRUITING city: Box Hill state: Victoria zip: 3128 country: Australia name: Svetlana Ivanic role: CONTACT email: svetlana.ivanic@monash.edu lat: -37.81887 lon: 145.12545 facility: Wantirna Health status: RECRUITING city: Wantirna state: Victoria zip: 3152 country: Australia name: Sarah Shue role: CONTACT lat: -37.85 lon: 145.21667 hasResults: False
nctId: NCT06339177 id: 10001899 id: 001899-I briefTitle: Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study overallStatus: RECRUITING date: 2024-05-01 date: 2030-10-01 date: 2031-04-01 date: 2024-04-01 date: 2024-04-26 name: National Institute of Allergy and Infectious Diseases (NIAID) class: NIH briefSummary: Background:
Participants may opt to continue their visits once a year for 3 more years. Participants may also opt for an extra clinial evaluation 1 week after starting a new treatment.... conditions: Lymphohistiocytosis, Hemophagocytic conditions: Secondary Hemophagocytic Lymphohistiocytosis conditions: Macrophage Activation Syndrome conditions: Hyperinflammatory Syndromes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Identify immunologic mechanisms involved in the pathogenesis of sHLH from a variety of predisposing conditions. measure: Prospectively define acute and longitudinal clinical profiles that predict key clinical outcomes. measure: Compare clinical and immune profiles between the classically defined HLH subgroups. measure: Improve the understanding of the pathogenesis of sHLH. measure: Characterize risk factors to identify populations at risk for developing sHLH. sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center status: RECRUITING city: Bethesda state: Maryland zip: 20892 country: United States name: NIH Clinical Center Office of Patient Recruitment (OPR) role: CONTACT phone: 800-411-1222 phoneExt: TTY dial 711 email: ccopr@nih.gov lat: 38.98067 lon: -77.10026 hasResults: False